Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind double-dummy placebo- and risperidone-controlled study of NHL35700 in schizophrenia
CTR20241006Phase 2Completed
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NHL35700 in schizophrenia, sponsored by Jiangsu Nhwa Pharmaceutical. Started Apr 2024; status: completed.
02
Drugs
NHL35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20241006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241006.